Dutasteride useful for enlarged prostate

Key points
- Dutasteride (also known as Avodart or Duprost) appears to have a variety of beneficial effects in treating benign prostatic hyperplasia (BPH), French researchers report.
- BPH, an enlargement of the prostate gland, is a common problem among older men that can cause symptoms such as frequent urination and a weak urine stream.
- Francois Desgrandchamps of Hopital Saint Louis, Paris and associates note that dutasteride has done well in research trials, providing significant improvements in symptoms and urinary flow, and has led to significant reductions in prostate size and the need for surgery.
- To find out if these benefits extended to patients in routine clinical practice, the researchers conducted a study with 366 men with BPH.
Dutasteride (also known as Avodart or Duprost) appears to have a variety of beneficial effects in treating benign prostatic hyperplasia (BPH), French researchers report.
BPH, an enlargement of the prostate gland, is a common problem among older men that can cause symptoms such as frequent urination and a weak urine stream. The problem can be effectively treated with a number of medications, but in more severe cases surgery is required.
Dr. Francois Desgrandchamps of Hopital Saint Louis, Paris and associates note that dutasteride has done well in research trials, providing significant improvements in symptoms and urinary flow, and has led to significant reductions in prostate size and the need for surgery. In addition, the drug appeared to be well tolerated with few side effects.
To find out if these benefits extended to patients in routine clinical practice, the researchers conducted a study with 366 men with BPH. All received dutasteride daily for 6 months.
By the end of the study, 72.5 percent of patients had at least a 3-point reduction in the International Prostate Symptom Score, a standard measure of BPH symptoms. On average, the score fell from 15.3 at the start of the study to 10.2 at 12 weeks and to 9.1 after 24 weeks, the researchers report in the medical journal BJU International.
Desgrandchamps' group found that quality of life scores also improved, as did measures of patient discomfort and satisfaction. The drug was well tolerated.
The investigators conclude that it is "interesting and encouraging" that the benefits of the drug seen in controlled clinical trials "are achievable and might actually be even greater in real-life clinical practice."
SOURCE: BJU International, July 2006.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsProstate cancer and treatment choices - a decision shared by doctor and patient?
When a man is diagnosed with localised prostate cancer, he usually faces a range of treatment options, from active surveillance to radiation therapy or surgical removal of the prostate. The patient's personal values and…
27 March 2015
NewsStudy examines association of inappropriate prostate, breast cancer imaging
An association of high rates of inappropriate imaging for prostate cancer and breast cancer identified in a study of Medicare beneficiaries suggests that, at the regional level, regional culture and infrastructure could…
13 March 2015
NewsBreast cancer risk may be increased in women who have first-degree relatives with a history of prostate cancer
Having a family history of prostate cancer among first-degree relatives may increase a woman's risk of developing breast cancer. That is the conclusion of a new study published early online in CANCER, a peer-reviewed…





